Application Nr Approved Date Route Status External Links
NDA018074 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications And Usage Fendique Er Is Indicated In The Management Of Exogenous Obesity As A Short Term Adjunct (a Few Weeks) In A Regimen Of Weight Reduction Based On Caloric Restriction In Patients With An Initial Body Mass Index (bmi) Of Greater Than Or Equal To 30 Kg/m 2 Or Greater Than Or Equal To 27 Kg/m 2 In The Presence Of Other Risk Factors (e.g., Controlled Hypertension, Diabetes, Hyperlipidemia) Who Have Not Responded To Appropriate Weight Reducing Regimen (diet And/or Exercise) Alone. Below Is A Chart Of Body Mass Index (bmi) Based On Various Heights And Weights. Bmi Is Calculated By Taking The Patient’s Weight, In Kilograms (kg), Divided By The Patient’s Height, In Meters (m), Squared. Metric Conversions Are As Follows: Pounds ÷ 2.2 = Kg; Inches × 0.0254 = Meters The Usefulness Of Agents Of This Class (see Clinical Pharmacology ) Should Be Measured Against Possible Risk Factors Inherent In Their Use Such As Those Described Below. Phendimetrazine Tartrate Is Indicated For Use As Monotherapy Only. Bmi-Chart

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Phendimetrazine Tartrate PHENDIMETRAZINE TARTRATE ZINC22010375

Comments